Zentalis Pharmaceuticals, Inc.
ZNTLDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 5, 2026
9dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
ZNTL Earnings Report
EPS Est: $-0.45 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ZNTL's past catalysts played out
ZN-d5
Amyloidosis
Niraparib
Ovarian Cancer
azenosertib
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ZN-c3
Uterine Serous Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ZN-d5 | Phase 2 | Amyloidosis | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
azenosertib | Phase 2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | - | - |
ZN-c3 | Phase 2 | Uterine Serous Carcinoma | - | - |
Ovarian Cancer
2 drugs in this indication
Amyloidosis
1 drug in this indication
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
1 drug in this indication
Uterine Serous Carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Zentalis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Zentalis Pharmaceuticals, Inc.'s (ZNTL) pipeline across Phase 2. Its lead program is ZN-d5 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zentalis Pharmaceuticals, Inc.'s next FDA catalyst?→
Zentalis Pharmaceuticals, Inc.'s (ZNTL) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZNTL biotech catalysts?→
Add ZNTL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zentalis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.